David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Recent debates over the use of sham surgery as a control for studies of fetal tissue transplantation for Parkinson’s disease have focused primarily on rival interpretations of the US federal regulations governing human-subjects research. Using the core ethical and methodological considerations that underwrite the equipoise requirement, we nd strong prima facie reasons against using sham surgery as a control in studies of cellular-based therapies for Parkinson’s disease and more broadly in clinical research. Additionally, we believe that these reasons can be generalized to apply to the use of other placebo controls that carry signi cant risks of positive harms in and of themselves. As a result, our arguments are centrally relevant to the emerging drive to subject therapies with a surgical component to the same rigorous standards of evaluation as those governing the approval of new pharmaceuticals.
|Keywords||No keywords specified (fix it)|
No categories specified
(categorize this paper)
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library||
References found in this work BETA
No references found.
Citations of this work BETA
R. L. Brim & F. G. Miller (2013). The Potential Benefit of the Placebo Effect in Sham-Controlled Trials: Implications for Risk-Benefit Assessments and Informed Consent. Journal of Medical Ethics 39 (11):703-707.
Similar books and articles
Howard Mann (2003). Sham Surgery in Randomized Trials: Additional Requirements Should Be Satisfied. American Journal of Bioethics 3 (4):5 – 7.
Connie Peck & Grahame Coleman (1991). Implications of Placebo Theory for Clinical Research and Practice in Pain Management. Theoretical Medicine and Bioethics 12 (3).
Jeremy Sugarman (2004). Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials. Science and Engineering Ethics 10 (1):29-35.
R. L. Albin (2005). Sham Surgery Controls Are Mitigated Trolleys. Journal of Medical Ethics 31 (3):149-152.
Joan Box (2004). Placebos and the UK Medical Research Council — and the Consumer Perspective. Science and Engineering Ethics 10 (1):95-101.
Franklin G. Miller & Howard Brody (2002). What Makes Placebo-Controlled Trials Unethical? American Journal of Bioethics 2 (2):3 – 9.
R. L. Albin (2002). Sham Surgery Controls: Intracerebral Grafting of Fetal Tissue for Parkinson's Disease and Proposed Criteria for Use of Sham Surgery Controls. Journal of Medical Ethics 28 (5):322-325.
Teresa Swift & Richard Huxtable (2013). The Ethics of Sham Surgery in Parkinson's Disease: Back to the Future? Bioethics 27 (4):175-185.
Franklin G. Miller (2004). Sham Surgery: An Ethical Analysis. Science and Engineering Ethics 10 (1):41-48.
Added to index2009-08-24
Total downloads8 ( #168,598 of 1,098,978 )
Recent downloads (6 months)1 ( #287,052 of 1,098,978 )
How can I increase my downloads?